STOCK TITAN

QIAGEN N.V. to Release Results for Q3 2021 and First Nine Months of 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

QIAGEN N.V. (NYSE: QGEN) has announced the release of its third quarter and year-to-date results scheduled for November 3, 2021. The report will be available at approximately 21:05 CET / 16:05 EDT. Following this, a conference call will occur on November 4 at 14:30 Frankfurt time where CEO Thierry Bernard and CFO Roland Sackers will discuss the results. Interested parties can access the call via multiple phone numbers, and a replay will be made available after the event.

Positive
  • Scheduled release of quarterly results on November 3, 2021, indicating ongoing transparency.
  • Conference call set for November 4, 2021, to provide insights directly from top executives.
Negative
  • None.

VENLO, the Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the third quarter and first nine months of 2021 on Wednesday, November 3, at approximately 21:05 Central European Time (CET) / 16:05 Eastern Daylight Time (EDT).

A conference call is scheduled for Thursday, November 4 at 14:30 Frankfurt time /13:30 London time/ 9:30 New York time. It will be hosted by Thierry Bernard, Chief Executive Officer, and Roland Sackers, Chief Financial Officer. (For Europe: Due to the U.S. time switch, the timing of our investor conference call will be held 30 minutes earlier than usual.)

Conference call and webcast details

Interested parties may listen to the call by dialing:

+1 929 477 0324 (U.S.), +44 (0)330 336 9127 (UK), +49 (0) 69 2222 25575 (Germany).

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
Conference ID: 9986160

The webcast will be accessible at:
https://globalmeet.webcasts.com/starthere.jsp?ei=1503232&tp_key=bd0c5f8a13

A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/starthere.jsp?ei=1503232&tp_key=bd0c5f8a13

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2021, QIAGEN employed approximately 5,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

John Gilardi

Vice President, Head of Corporate Communications and Investor Relations

+49 2103 29 11711

+1 240 686 2222

Email: ir@qiagen.com

Phoebe Loh

Senior Director Investor Relations

+49 2103 29 11457

Email: ir@qiagen.com

Source: QIAGEN N.V.

FAQ

When will QIAGEN release its third quarter results?

QIAGEN will release its third quarter results on November 3, 2021.

What time is the QIAGEN conference call scheduled?

The QIAGEN conference call is scheduled for November 4, 2021, at 14:30 Frankfurt time.

Who will host the QIAGEN conference call?

The conference call will be hosted by CEO Thierry Bernard and CFO Roland Sackers.

How can I access the QIAGEN conference call?

You can access the QIAGEN conference call by dialing specific numbers for the U.S., UK, and Germany.

Is there a replay available for the QIAGEN conference call?

Yes, a replay of the QIAGEN conference call will be available after the event.

QIAGEN N.V.

NYSE:QGEN

QGEN Rankings

QGEN Latest News

QGEN Stock Data

9.06B
217.27M
2.24%
87.65%
1.6%
Diagnostics & Research
Healthcare
Link
United States of America
Venlo